This bill reauthorizes the federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs and updates program rules to push more funding toward commercialization, broaden participation, and simplify transition to Phase III (non‑SBIR) government purchases. It keeps the SBIR/STTR architecture but layers in new spending targets, reporting requirements, pilot extensions, and assistance programs intended to accelerate R&D into real products and increase participation by underrepresented institutions.
Practically, the measure raises agency set‑aside levels over time, creates a fellowship/internship authority for Phase II awardees, expands technical and business assistance (with explicit per‑project dollar caps), requires richer public reporting on subcontracted research partners, and codifies ownership and foreign‑linked investor safeguards. The bill also directs procurement training, names Technology Commercialization Officials at agencies, and mandates new commercialization impact metrics for assessing program returns — changes that will affect agencies, small R&D firms, research institutions, and investors in distinct ways.
At a Glance
What It Does
Reauthorizes SBIR/STTR and increases the share of R&D budgets agencies must set aside for those programs; creates fellowship authority for Phase II awardees; mandates enhanced outreach and richer public reporting; and requires agencies to streamline Phase III contracting and train acquisition staff.
Who It Affects
Federal agencies that run SBIR/STTR programs (for example, DoD, NIH, DOE, NASA, NSF), small businesses that win SBIR/STTR awards (including those with university subcontracts and SBIC‑backed firms), minority‑serving institutions, venture‑backed companies, and procurement/acquisition offices that handle Phase III purchases.
Why It Matters
The bill shifts program priorities from pure R&D toward commercialization and wider geographic and demographic participation by (a) increasing funding floors, (b) tying program officers and contracting staff into commercialization goals, and (c) demanding new data and assessments that will be used to judge program performance and allocation decisions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill keeps SBIR and STTR in place and extends authorities now set to expire, but it is primarily a modernization package. It phases up agency set‑aside percentages for SBIR and STTR over several fiscal years (moving agencies toward higher percentages on a defined schedule), extends several pilot programs through 2030, and provides the SBA with longer planning horizons.
Those increases create predictable, rising pools of money for small‑business R&D while also creating tradeoffs inside agency R&D budgets.
To broaden participation, the bill funds outreach and application assistance, directs agencies to enhance recruitment of researchers at minority‑serving institutions and underrepresented States, and requires public website fields that identify subcontracted research institutions and classify them by institution type (HBCU, Hispanic‑serving, Tribal, etc.). Agencies may also fund fellowships and internships tied to Phase II awardees, and may partner with nonprofit support organizations to reach women and socially or economically disadvantaged individuals.On commercialization, the bill tightens the pipeline to Phase III.
It requires contracting workforce training on Phase III acquisitions and data rights, directs agencies to designate Technology Commercialization Officials to coordinate commercialization pathways and to advocate internally for Phase III transitions, and instructs agencies to standardize solicitation language and model clauses to reduce contracting friction. It also expands direct‑to‑Phase II authority to all required SBIR agencies while capping the share of total SBIR funds that may be used for those awards (with an elevated cap for NIH).The bill retools assistance: it authorizes per‑project technical and business assistance budgets (explicitly up to $6,500 for Phase I and $50,000 for Phase II) that recipients may use for vendors, staffing, cybersecurity, IP counseling, or I‑Corps participation.
It also requires agencies to report Phase I/II/III awards, subcontractor institution details, and other commercialization indicators to the public database and to Congress, and it creates an annual commercialization impact assessment that aggregates revenues, other government awards, M&A, and Phase III counts for active award recipients.Finally, the bill inserts guardrails around ownership and national‑security risk: it codifies limits on small businesses majority‑owned by multiple venture capital operating companies, hedge funds, or private equity firms where ownership links to covered foreign entities, expands due diligence pilot authority to assess security risks, and clarifies that Small Business Investment Companies (SBICs) are included in the statutory picture.
The Five Things You Need to Know
SBIR/STTR set‑aside schedule: the bill phases agency SBIR set‑asides up in steps — at least 4% in FY2026–27, 5% in FY2028–29, 6% in FY2030–31, and 7% in FY2032 and thereafter — and raises STTR from current levels to 0.5% (FY2026–27), 0.65% (FY2028–29), 0.8% (FY2030–31) and 1% (FY2032+).
Fellowships: agencies may fund fellowships and internships tied to Phase II awardees and must carry out enhanced outreach to women, socially disadvantaged, and economically disadvantaged individuals; agencies not using specific pilot funds for this purpose are limited to using no more than 3% of the required SBIR/STTR expenditures for such programs.
Technical/business assistance caps: recipients may use program‑authorized funding for assistance — up to $6,500 per Phase I project and up to $50,000 per Phase II project — and may use that funding to hire staff, augment teams, purchase vendor services including cybersecurity/IP counseling, or participate in I‑Corps equivalents.
Direct‑to‑Phase II expansion and cap: the bill extends direct‑to‑Phase II authority to every SBIR agency and extends the pilot through FY2030, but caps direct‑to‑Phase II awards at 10% of an agency’s SBIR allocation in a fiscal year (15% cap specifically for NIH).
Database and public reporting: the bill requires the SBIR/STTR public database to include Phase I/II/III entries and to list subcontracted research institutions (name, location and classification such as HBCU, Hispanic‑serving, federally funded R&D center), and it creates a commercialization impact assessment and annual reporting to Congress.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Reauthorization and FAST extension
This Title removes the previous sunset language and extends program authority through subsequent fiscal years; it also extends the FAST program timeline to 2030. For practitioners, the immediate effect is legal continuity: agencies retain statutory authority to run SBIR and STTR without a lapse and FAST administrative options remain available through FY2030. That continuity allows agencies and awardees to plan commercialization and outreach activities with multi‑year horizons.
Competition, fellowships, outreach, and assistance
This cluster raises statutory set‑aside floors for SBIR and STTR on a multi‑year schedule, adds a new fellowship/internship authority tied to Phase II recipients with mandated enhanced outreach, and requires agencies to fund application assistance targeted at States and institutions with historically low participation. It also materially revises technical and business assistance rules: agencies must authorize recipients to select assistance and may now explicitly fund staff costs, cybersecurity help, IP counseling, and I‑Corps participation; the statute sets explicit per‑project caps ($6,500 Phase I; $50,000 Phase II), which agencies will need to operationalize in award documents and program guidance.
Commercialization workforce, officials, and Phase III simplification
Title III targets the Phase III transition. It requires agencies to set up acquisition workforce training on Phase III deals and the use of data rights, and it requires each agency to designate (or identify) a Technology Commercialization Official responsible for coordinating commercialization pathways internally and across agencies. The statute also directs Procurement Center Representatives and agencies to advocate for Phase III transitions, and it orders development of simplified model clauses and standardized solicitation language to reduce friction when a small firm moves from SBIR/STTR award to a government contract or prime subcontract.
Pilot programs, direct‑to‑Phase II, and due diligence
This Title extends multiple pilots through 2030 and increases the administrative transfer pot slightly (from 3% to 3.3%) while authorizing a mandated transfer of at least 10% of certain agencies’ program processing funds to the SBA for administration. It broadens direct‑to‑Phase II authority to all SBIR agencies, sets a statutory cap on its use (10% agency cap; 15% NIH exception), extends commercialization readiness pilots, and authorizes extension of due diligence pilots to assess security risks — a concrete operational change for agencies that want to accelerate or expand direct entry into Phase II.
Oversight, reporting, GAO study, and ownership safeguards
This Title strengthens transparency and oversight. It expands who receives annual reports (adds House and Senate small business committees and requires web publication), extends award timeliness reporting, tasks the GAO with a 3‑year report on diversification and commercialization, and creates a commercialization impact assessment with defined metrics (revenues, non‑SBIR federal awards, M&A, Phase III awards). Critically, it codifies new eligibility limits for small businesses majority‑owned by multiple VC/PE/hedge funds if those ownership chains connect to ‘covered foreign entities,’ and it defines covered foreign entities broadly, creating new compliance obligations for entities with complex ownership.
Technical edits: SBICs and Phase III labeling
This last Title makes technical edits to include Small Business Investment Companies (SBICs) in the statutory crosswalk for ownership and investment considerations and clarifies headings and language around Phase III and sole‑source procurement justification. Practically, this draws SBIC investments into the same regulatory frame that governs other investor ownership questions for SBIR/STTR eligibility and reporting.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small R&D firms with viable commercialization paths — higher SBIR/STTR set‑asides and stronger Phase III advocacy increase the pool of agency buyers and create clearer internal champions and training that can shorten the path from lab to customer.
- Minority‑serving and other underrepresented research institutions — the database and outreach rules force agencies and awardees to surface subcontracting relationships and push targeted outreach, making partnership opportunities and visibility to federal solicitations more likely.
- Phase II awardees and trainees — the new fellowship/internship authority and permitted uses of assistance funds create paid training and hiring pathways at multiple educational levels, expanding talent pipelines into small‑firm commercialization efforts.
- Agencies focused on acquisition outcomes — Technology Commercialization Officials and procurement training give agency acquisition teams tools to recognize commercialization opportunities and complete Phase III purchases more efficiently.
- SBICs and regulated fund investors — explicit inclusion of SBICs in the statute removes ambiguity about how SBIC investment interacts with SBIR/STTR ownership rules, giving those investors clearer expectations.
Who Bears the Cost
- Federal agencies (especially large R&D agencies) — higher SBIR/STTR set‑aside floors and pilot transfer mandates increase the portion of R&D budgets earmarked for small businesses and may crowd other account priorities, requiring internal reprogramming.
- SBA and agency program offices — new data fields, a commercialization impact assessment, expanded reporting, and fund‑transfer mechanics increase administrative workload and will require investment in IT and staff time to comply.
- VC/PE‑majority owned small business concerns — the bill creates new eligibility checks tied to foreign ownership and ‘covered foreign entities’ that could disqualify firms or force structural changes to remain eligible for awards.
- Acquisition workforce and contracting officers — they must undertake training and adopt model clauses, which creates near‑term workload and resource requirements, and prime contractors may need to adjust subcontracting plans to fit standardized Phase III language.
- Research institutions subcontracted to SBIR/STTR awardees — they will be publicly identified in databases and may face additional contract reporting obligations and scrutiny, requiring administrative support to comply.
Key Issues
The Core Tension
The central dilemma is simple but unavoidable: the bill pushes the SBIR/STTR system to deliver more commercialization, measurable economic return, and broader participation — goals that require tighter reporting, faster acquisition pipelines, and active stewardship — but achieving those aims risks squeezing mission‑driven research, imposing heavy administrative burdens, and complicating private investment structures. Policymakers must choose between faster, more market‑oriented outcomes and preserving the flexible, low‑barrier R&D ecosystem that historically attracted early‑stage science and technology firms.
The bill stitches together several distinct priorities — commercialization, equity of participation, and heightened national‑security screening — but each creates implementation tradeoffs. Raising set‑aside percentages gives small innovators more money on paper but reallocates funds within often‑fixed agency R&D budgets; agencies will need to choose whether to cut other internal programs, reprogram funds, or seek additional appropriations.
That reallocation could slow noncommercial basic research or change the profile of agency awards.
The expanded reporting and commercialization assessment will improve transparency but also imposes data collection, privacy, and definitional burdens. Agencies must determine how to collect historic revenue and M&A data from small firms (some of which are reluctant to disclose sensitive commercial details), and SBA must build the database fields and verification systems.
The commercialization assessment uses lookbacks over nine years and applies to firms meeting an unusual statutory trigger (a firm “that has received not less than 50 Phase II” awards in a specified window) — the language may create edge cases and enforcement ambiguity that will require regulatory clarification.
The ownership and security provisions balance two competing objectives — keeping sensitive technologies out of risky ownership chains and preserving the attractiveness of SBIR/STTR to private investors. The statute’s broad definition of “covered foreign entity” and the new ineligibility rule for firms majority‑owned by multiple venture/hedge/PE investors where foreign links exist could chill investment structures or force complex restructuring.
Agencies and SBA will need granular guidance to determine when ownership reaches the statutory threshold, how to treat indirect investment, and how to coordinate with export control and national‑security reviews, which risks slowing award decisions unless well resourced and harmonized across agencies.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.